The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibition.

Checkpoint inhibitor immunotherapy plus tyrosine kinase inhibitor (IO/TKI) has become the first‐line treatment for metastatic renal cell carcinoma (RCC), despite the lack of biomarkers. Cyclin‐dependent kinase 6 (CDK6) has shown a regulatory role in antitumour response. The study enrolled two cohorts of metastatic RCC treated by IO/TKI (Zhongshan Hospital [ZS]‐MRCC, n = 45; JAVELIN‐101, n = 726) and two cohorts of localized RCC (ZS‐HRRCC, n = 40; TCGA‐KIRC, n = 530). CDK6 was evaluated by RNA‐sequencing. Progression‐free survival (PFS) was the primary endpoint. The prognostic role of CDK6 was evaluated by survival analysis. The correlation between CDK6 and tumour microenvironment was assessed by immunohistochemistry and flow cytometry. The high‐CDK6 group displayed a lower response rate (13.6%) than the low‐CDK6 group (56.5%) (P =.002). High‐CDK6 was associated with poor PFS in both the ZS‐MRCC cohort (high‐CDK6, median PFS 6.4 months; low‐CDK6, median PFS not reached; P =.010) and JAVELIN‐101 cohort (high‐CDK6, median PFS 10.0 months; low‐CDK6, median PFS 13.3 month; P =.033). High‐CDK6 was associated with increased PD1+CD8+ T cells (Spearman's ρ =.47, P <.001) and decreased Granzyme B+CD8+ T cells (Spearman's ρ = −.35, P =.030). Finally, a random forest score (RFscore) was built by integrating CDK6 and immunologic genes, which was associated with survival benefits of IO/TKI (RFscore‐low, TKI vs IO/TKI, HR = 2.47, 95% CI 1.82–3.35, P <.001; RFscore‐high, TKI vs IO/TKI, HR = 0.99, 95% CI 0.75–1.32, P =.963). Elevated CDK6 expression indicated resistance and poor PFS under IO/TKI therapy, which was related to exhausted CD8+ T cells. Integrated RFscore could evaluate the benefits of IO/TKI. [ABSTRACT FROM AUTHOR]